Better Buy: Pfizer Inc. vs. Johnson & Johnson

on

Pfizer and Johnson & Johnson are both top dividend stocks. But which stock is the better buy right now?



Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ) are both considered top dividend stocks because they offer higher-than-average yields for healthcare stocks, strong free cash flows, and a lengthy history of regular increases to their payouts.

That said, J&J has been the clear favorite among investors over the past decade based on its performance. According to S&P Global Market Intelligence, for instance, J&J's stock has crushed both the broader markets and Pfizer during this period.

With Pfizer set to merge with Allergan (NYSE:AGN) later this year and J&J starting to see a drop off in its high-growth pharma business, though, these two blue chip stocks could see their fortunes change moving forward. Armed with this insight, let's consider which stock is the better long-term buy right now...
Source: The Motley Fool